The Short Answer
The AREDS2 trial proved benefit specifically for people with intermediate age-related macular degeneration (AMD) or advanced AMD in one eye. If you have early AMD or normal vision, the evidence is weaker; if you have advanced AMD in both eyes, supplementation may still slow remaining vision loss [3].
AREDS2 enrolled only people aged 50–85 with intermediate AMD (medium-sized drusen or pigment changes) or advanced AMD in one eye [3]. This population showed clear 25% slowing of progression over five years. If you have early AMD (small drusen only) or normal vision, the trial didn't test you—so the benefit is unproven, though some eye doctors recommend it for prevention [4].
Your eye naturally contains lutein and zeaxanthin, but macular pigment density declines with age, smoking, and sun exposure [6]. Supplementation rebuilds this protective layer by increasing macular pigment optical density (MPOD) measurably within 8–12 weeks [2]. People with low dietary intake of leafy greens (spinach, kale, collards) or those with genetic variations in carotenoid absorption may benefit most [1].
If you have advanced AMD in both eyes, supplementation won't restore lost vision, but it may slow further progression in remaining retinal areas [5]. Talk to your eye doctor about your specific retinal findings—OCT imaging or fundus photography—before starting. Supplementation works best as part of a complete AMD strategy: smoking cessation, UV protection, blood pressure control, and antioxidant-rich diet [3].